The Use of Inhaled Epoprostenol for Acute Respiratory Distress Syndrome Secondary Due To COVID-19: a Case Series.

IF 1.4 3区工程技术 Q2 ENGINEERING, MULTIDISCIPLINARY Journal of Elasticity Pub Date : 2021-11-17 eCollection Date: 2022-01-01 DOI:10.2478/jccm-2021-0037

Komal Imtiaz, Wade Jodeh, Dave Sudekum, Bruno DiGiovine, Jason Hecht

{"title":"The Use of Inhaled Epoprostenol for Acute Respiratory Distress Syndrome Secondary Due To COVID-19: a Case Series.","authors":"Komal Imtiaz, Wade Jodeh, Dave Sudekum, Bruno DiGiovine, Jason Hecht","doi":"10.2478/jccm-2021-0037","DOIUrl":null,"url":null,"abstract":"Introduction: Inhaled epoprostenol (iEpo) is a pulmonary vasodilator used to treat refractory respiratory failure, including that caused by Coronavirus 2019 (COVID-19) pneumonia.Aim of study: To describe the experience at three teaching hospitals using iEpo for severe respiratory failure due to COVID-19 and evaluate its efficacy in improving oxygenation.Methods: Fifteen patients were included who received iEpo, had confirmed COVID-19 and had an arterial blood gas measurement in the 12 hours before and 24 hours after iEpo initiation.Results: Eleven patients received prone ventilation before iEpo (73.3%), and six (40%) were paralyzed. The partial pressure of arterial oxygen to fraction of inspired oxygen (P/F ratio) improved from 95.7 mmHg to 118.9 mmHg (p=0.279) following iEpo initiation. In the nine patients with severe ARDS, the mean P/F ratio improved from 66.1 mmHg to 95.7 mmHg (p=0.317). Ultimately, four patients (26.7%) were extubated after an average of 9.9 days post-initiation.Conclusions: The findings demonstrated a trend towards improvement in oxygenation in critically ill COVID-19 patients. Although limited by the small sample size, the results of this case series portend further investigation into the role of iEpo for severe respiratory failure associated with COVID-19.","PeriodicalId":624,"journal":{"name":"Journal of Elasticity","volume":"39 2","pages":"33-40"},"PeriodicalIF":1.4000,"publicationDate":"2021-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852286/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Elasticity","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/jccm-2021-0037","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ENGINEERING, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Inhaled epoprostenol (iEpo) is a pulmonary vasodilator used to treat refractory respiratory failure, including that caused by Coronavirus 2019 (COVID-19) pneumonia.

Aim of study: To describe the experience at three teaching hospitals using iEpo for severe respiratory failure due to COVID-19 and evaluate its efficacy in improving oxygenation.

Methods: Fifteen patients were included who received iEpo, had confirmed COVID-19 and had an arterial blood gas measurement in the 12 hours before and 24 hours after iEpo initiation.

Results: Eleven patients received prone ventilation before iEpo (73.3%), and six (40%) were paralyzed. The partial pressure of arterial oxygen to fraction of inspired oxygen (P/F ratio) improved from 95.7 mmHg to 118.9 mmHg (p=0.279) following iEpo initiation. In the nine patients with severe ARDS, the mean P/F ratio improved from 66.1 mmHg to 95.7 mmHg (p=0.317). Ultimately, four patients (26.7%) were extubated after an average of 9.9 days post-initiation.

Conclusions: The findings demonstrated a trend towards improvement in oxygenation in critically ill COVID-19 patients. Although limited by the small sample size, the results of this case series portend further investigation into the role of iEpo for severe respiratory failure associated with COVID-19.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

吸入式依前列醇治疗新冠肺炎继发急性呼吸窘迫综合征：病例系列

摘要简介吸入依前列醇（iEpo）是一种用于治疗难治性呼吸衰竭的肺血管舒张剂，包括2019冠状病毒（新冠肺炎）肺炎引起的呼吸衰竭。研究目的描述三家教学医院使用iEpo治疗新冠肺炎引起的严重呼吸衰竭的经验，并评估其改善氧合的效果。方法15例患者接受了iEpo治疗，确诊为新冠肺炎，并在iEpo启动前12小时和启动后24小时内进行了动脉血气测量。结果11例患者在iEpo前接受俯卧通气（73.3%），6例患者（40%）瘫痪。iEpo启动后，动脉氧分压与吸入氧分压（P/F比）从95.7mmHg提高到118.9mmHg（P=0.279）。在9名严重ARDS患者中，平均P/F比从66.1 mmHg提高到95.7 mmHg（P=0.317）。最终，4名患者（26.7%）在开始后平均9.9天拔管。结论研究结果表明，危重新冠肺炎患者的氧合有改善的趋势。尽管受小样本量的限制，但该病例系列的结果预示着对iEpo在新冠肺炎相关严重呼吸衰竭中的作用的进一步调查。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Elasticity 工程技术-材料科学：综合

CiteScore

3.70

自引率

15.00%

发文量

审稿时长

>12 weeks

期刊介绍： The Journal of Elasticity was founded in 1971 by Marvin Stippes (1922-1979), with its main purpose being to report original and significant discoveries in elasticity. The Journal has broadened in scope over the years to include original contributions in the physical and mathematical science of solids. The areas of rational mechanics, mechanics of materials, including theories of soft materials, biomechanics, and engineering sciences that contribute to fundamental advancements in understanding and predicting the complex behavior of solids are particularly welcomed. The role of elasticity in all such behavior is well recognized and reporting significant discoveries in elasticity remains important to the Journal, as is its relation to thermal and mass transport, electromagnetism, and chemical reactions. Fundamental research that applies the concepts of physics and elements of applied mathematical science is of particular interest. Original research contributions will appear as either full research papers or research notes. Well-documented historical essays and reviews also are welcomed. Materials that will prove effective in teaching will appear as classroom notes. Computational and/or experimental investigations that emphasize relationships to the modeling of the novel physical behavior of solids at all scales are of interest. Guidance principles for content are to be found in the current interests of the Editorial Board.